Search

Your search keyword '"Kivitz, Alan J"' showing total 3 results
Start Over Author "Kivitz, Alan J" Database Gale General OneFile
3 results on '"Kivitz, Alan J"'

1. Denosumab in postmenopausal women with low bone mineral density

Author

McClung, Michael, Miller, Paul D., Zhang, Charlie, Woodson, Grattan C., Cohen, Stanley B., Lewiecki, Michael, Lain, Douglas, Kivitz, Alan J., Holloway, Donna L., Bolognese, Michael A., Moffett, Alfred H., Bekker, Pirow J., Peterson, Mark C., Peacock, Munro, Lederman, Samuel N., and Chestnut, Charles H.

Subjects
Postmenopausal women -- Health aspects, Osteoporosis -- Drug therapy, Bones -- Density, Bones -- Health aspects
Abstract

Receptor activator of nuclear factor-kB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival and the fully human monoclonal antibody denosumab binds RANKL with high affinity and specificity and inhibits RANKL action. In postmenopausal women with low bone mass, denosumab increased bone material density and decreased bone resorption, which suggests that denomusab might be an effective treatment for osteoporosis.

Published
2006

2. Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis:A Randomized Controlled Trial

Author

Simon, Lee S., Weaver, Arthur L., Graham, David Y., Kivitz, Alan J., Lipsky, Peter E., Hubbard, Richard C., Isakson, Peter C., Verburg, Kenneth M., Yu, Shawn S., Zhao, William W., and Geis, C. Steven

Subjects
Rheumatoid arthritis -- Drug therapy, Nonsteroidal anti-inflammatory drugs -- Evaluation
Abstract

The drug celecoxib appears to be an effective painkiller in patients with rheumatoid arthritis and is less likely than other arthritis drugs to damage the gastrointestinal tract. Celecoxib inhibits an enzyme called cyclooxygenase 2 (COX-2). Researchers randomly assigned 1,149 patients with rheumatoid arthritis to take one of several dosages of celecoxib, naproxen or a placebo, or inactive substance. Both celecoxib and naproxen caused reduced pain, but celecoxib was less likely to cause ulcers. Thirty-one percent of those who took naproxen had a gastrointestinal side effect compared to about 25% of the celecoxib users and 19% of the placebo users.

Published
1999

3. Efficacy and safety of Rofecoxib 12.5 mg versus Nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial

Author

Kivitz, Alan J., Greenwald, Maria W., Cohen, Stanley B., Polis, Adam B., Najarian Daryl K., Dixon, Mary E., Moidel, Robert A., Green, Jerry A., Baraf, Herbert S.B., Petruschke, Richard A., Matsumoto, Alan K., and Geba, Gregory P.

Subjects
Nabumetone -- Dosage and administration, Rofecoxib -- Dosage and administration, Osteoarthritis -- Development and progression, Aged -- Health aspects, Health, Seniors
Abstract

The structural development of osteoarthritis (OA) is generally gradual over a lifespan, with the disorder affecting up to 80 percent of the population of the United States by age 65 and virtually everyone aged 75 and older. An evaluation of the usage of starting doses of rofecoxib and nabumetone in patients with OA of the knee is illustrated.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results